Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)

The molecular chaperone heat shock protein 90 (Hsp90) is a current inhibition target for the treatment of diseases, including cancer. In humans, there are two major cytosolic isoforms of Hsp90 (Hsp90α and Hsp90β). Hsp90α is inducible and Hsp90β is constitutively expressed. Most Hsp90 inhibitors are pan-inhibitors that target both cytosolic isoforms of Hsp90. The development of isoform-selective inhibitors of Hsp90 may enable better clinical outcomes. Herein, by using virtual screening and binding studies, we report our work in the identification and characterisation of novel isoform-selective ligands for the middle domain of Hsp90β. Our results pave the way for further development of isoform-selective Hsp90 inhibitors.

[1]  J. Buchner,et al.  Structure, Function, and Regulation of the Hsp90 Machinery. , 2019, Cold Spring Harbor perspectives in biology.

[2]  F. Esposito,et al.  HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy , 2019, Cells.

[3]  Luke Whitesell,et al.  HSP90: Enabler of Cancer Adaptation , 2019, Annual Review of Cancer Biology.

[4]  J. Reynisson,et al.  The Development of a Weighted Index to Optimise Compound Libraries for High Throughput Screening , 2018, Molecular informatics.

[5]  M. El-Sabban,et al.  The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease , 2018, International journal of molecular sciences.

[6]  Michael L. Wang,et al.  Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. , 2018, Blood advances.

[7]  D. Ho,et al.  Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner , 2018, Oncotarget.

[8]  L. Neckers,et al.  Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development , 2018, Cell Stress and Chaperones.

[9]  Junpeng Deng,et al.  Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor , 2018, Nature Communications.

[10]  C. Passaglia,et al.  Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma , 2017, Scientific Reports.

[11]  T. Chou,et al.  Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models , 2017, Oncotarget.

[12]  J. Reynisson,et al.  Virtual screening and biophysical studies lead to HSP90 inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[13]  C. Prodromou.  Mechanisms of Hsp90 regulation , 2016, The Biochemical journal.

[14]  J. Onuchic,et al.  Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β , 2016, Proceedings of the National Academy of Sciences.

[15]  B. Blagg,et al.  Natural Product Inspired N‐Terminal Hsp90 Inhibitors: From Bench to Bedside? , 2016, Medicinal research reviews.

[16]  L. Neckers,et al.  Regulation and function of the human HSP90AA1 gene. , 2015, Gene.

[17]  B. Blagg,et al.  KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells , 2015, Molecular Pharmacology.

[18]  Saijuan Chen,et al.  Vibsanin B Preferentially Targets HSP90β, Inhibits Interstitial Leukocyte Migration, and Ameliorates Experimental Autoimmune Encephalomyelitis , 2015, The Journal of Immunology.

[19]  R. Bhat,et al.  Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. , 2014, Journal of medicinal chemistry.

[20]  L. Paz-Ares,et al.  Inhibition of HSP90 molecular chaperones: moving into the clinic. , 2013, The Lancet. Oncology.

[21]  R. Kurzrock,et al.  Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. , 2013, Cancer treatment reviews.

[22]  J. Buchner,et al.  Structure, Function and Regulation of the Hsp90 Machinery , 2013, Biomedical journal.

[23]  Luan Wang,et al.  Hsp90 Inhibitors and the Reduction of Anti-Cancer Drug Resistance by Non-Genetic and Genetic Mechanisms , 2012, Pharmaceuticals.

[24]  S. Gambhir,et al.  Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects , 2012, Proceedings of the National Academy of Sciences.

[25]  Shaoguang Li,et al.  Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies , 2012, Pharmaceuticals.

[26]  C. Nicchitta,et al.  Development of a Grp94 inhibitor. , 2012, Journal of the American Chemical Society.

[27]  Philip F. Hughes,et al.  A highly selective Hsp90 affinity chromatography resin with a cleavable linker. , 2012, Bioorganic & medicinal chemistry.

[28]  Xiangyi Lu,et al.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. , 2012, Biochemical pharmacology.

[29]  Jill L. Johnson.  Evolution and function of diverse Hsp90 homologs and cochaperone proteins. , 2012, Biochimica et biophysica acta.

[30]  Tony Taldone,et al.  Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. , 2012, Biochimica et biophysica acta.

[31]  C. Prodromou.  The ‘active life’ of Hsp90 complexes☆ , 2012, Biochimica et biophysica acta.

[32]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[33]  D. Proia,et al.  Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy , 2011, Molecular Cancer Therapeutics.

[34]  Jóhannes Reynisson,et al.  Characteristics of known drug space. Natural products, their derivatives and synthetic drugs. , 2010, European journal of medicinal chemistry.

[35]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[36]  S. Lindquist,et al.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.

[37]  Jill L. Johnson,et al.  Hsp90 and co-chaperones twist the functions of diverse client proteins. , 2010, Biopolymers.

[38]  Zihai Li,et al.  17 AAG for HSP90 inhibition in cancer--from bench to bedside. , 2009, Current molecular medicine.

[39]  K. Bhalla,et al.  Targeting HSP90 for cancer therapy , 2009, British Journal of Cancer.

[40]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[41]  B. Blagg,et al.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. , 2008, Current medicinal chemistry.

[42]  Biao He,et al.  Inhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  Tony Taldone,et al.  Targeting Hsp90: small-molecule inhibitors and their clinical development. , 2008, Current opinion in pharmacology.

[44]  Jóhannes Reynisson,et al.  Benchmarking the reliability of QikProp. Correlation between experimental and predicted values , 2008 .

[45]  A. Taherian,et al.  A comparison of Hsp90alpha and Hsp90beta interactions with cochaperones and substrates. , 2008, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[46]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[47]  Paul Workman,et al.  Inhibitors of the heat shock response: Biology and pharmacology , 2007, FEBS letters.

[48]  Marco Siderius,et al.  The Middle Domain of Hsp90 Acts as a Discriminator between Different Types of Client Proteins , 2006, Molecular and Cellular Biology.

[49]  M. Drysdale,et al.  Targeting Hsp90 for the treatment of cancer. , 2006, Current opinion in drug discovery & development.

[50]  Bin Chen,et al.  Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms , 2006, BMC Genomics.

[51]  L. Pearl,et al.  Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.

[52]  D. van der Spoel,et al.  Blind docking of drug‐sized compounds to proteins with up to a thousand residues , 2006, FEBS letters.

[53]  Marcel L Verdonk,et al.  General and targeted statistical potentials for protein–ligand interactions , 2005, Proteins.

[54]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[55]  Y. Miyata,et al.  Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. , 2005, Current pharmaceutical design.

[56]  L. Pearl,et al.  Co-chaperone Regulation of Conformational Switching in the Hsp90 ATPase Cycle* , 2004, Journal of Biological Chemistry.

[57]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[58]  D. Solit,et al.  Hsp90: the vulnerable chaperone. , 2004, Drug discovery today.

[59]  Hong Zhang,et al.  Hsp90 Activation and Cell Cycle Regulation , 2004, Cell cycle.

[60]  P. Csermely,et al.  Hsp90 isoforms: functions, expression and clinical importance , 2004, FEBS letters.

[61]  Joyce Cheung-Flynn,et al.  Functional Specificity of Co-Chaperone Interactions with Hsp90 Client Proteins , 2004, Critical reviews in biochemistry and molecular biology.

[62]  Haruki Nakamura,et al.  Announcing the worldwide Protein Data Bank , 2003, Nature Structural Biology.

[63]  Xiuying Xiao,et al.  Significance of expression of heat shock protein90α in human gastric cancer , 2003 .

[64]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[65]  Chrisostomos Prodromou,et al.  Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. , 2003, Molecular cell.

[66]  A. Mizuno,et al.  A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone. , 2002, European journal of biochemistry.

[67]  D. van der Spoel,et al.  Efficient docking of peptides to proteins without prior knowledge of the binding site , 2002, Protein science : a publication of the Protein Society.

[68]  Shaomeng Wang,et al.  How Does Consensus Scoring Work for Virtual Library Screening? An Idealized Computer Experiment , 2001, J. Chem. Inf. Comput. Sci..

[69]  L. Pearl,et al.  Structure and in vivo function of Hsp90. , 2000, Current opinion in structural biology.

[70]  M. Murcko,et al.  Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. , 1999, Journal of medicinal chemistry.

[71]  R. Jaenicke,et al.  The charged region of Hsp90 modulates the function of the N-terminal domain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[72]  N. Wu,et al.  Regulation of human hsp90α gene expression , 1999, FEBS letters.

[73]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[74]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[75]  J. Buchner,et al.  Chaperone Function of Hsp90-Associated Proteins , 1996, Science.

[76]  E. Baulieu,et al.  Mutational analysis of Hsp90 alpha dimerization and subcellular localization: dimer disruption does not impede "in vivo' interaction with estrogen receptor. , 1996, Journal of cell science.

[77]  L. Whitesell,et al.  Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. , 1996, Molecular endocrinology.

[78]  R. Gupta,et al.  Phylogenetic analysis of the 90 kD heat shock family of protein sequences and an examination of the relationship among animals, plants, and fungi species. , 1995, Molecular biology and evolution.

[79]  P. Russell,et al.  A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. , 1994, The EMBO journal.

[80]  L. Weber,et al.  Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein , 1989, Molecular and cellular biology.

[81]  Norman L. Allinger,et al.  Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms , 1977 .

[82]  K. Jhaveri,et al.  HSP90 inhibitors for cancer therapy and overcoming drug resistance. , 2012, Advances in pharmacology.

[83]  C. Nicchitta,et al.  Development of a Grp 94 inhibitor , 2012 .